Benefits of investing

A looming patent cliff presents another challenge for Pfizer. However, the company has multiple drugs with fast-growing sales that should largely offset any revenue declines from patent expirations. Pfizer's business development deals and pipeline progress should also help boost sales and profits. J.P. Morgan CLO BB Index is a subset of the CLOIE index that only tracks the BB rated CLO. Increased infrastructure spending suggests sustained earnings growth, leading analysts to raise 12-month target prices by an average of 6%.